Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Eli Lilly and Company
Canadian Cancer Trials Group
Saitama Medical University International Medical Center
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Yale University
University of Louisville
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
SWOG Cancer Research Network
Washington University School of Medicine
University of Miami
Hoosier Cancer Research Network
M.D. Anderson Cancer Center
GOG Foundation
University of Arizona
Hellenic Oncology Research Group
Duke University
Merck Sharp & Dohme LLC
SWOG Cancer Research Network
University of Southern California
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
GOG Foundation
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Azaya Therapeutics, Inc.
Sanofi
Sanofi
Dana-Farber Cancer Institute
Montefiore Medical Center
Fred Hutchinson Cancer Center
Sanofi
National Cancer Institute (NCI)
Sanofi